Clinical Trial

Evaluation of Left Ventricular Function to Predict Weaning Success in the Intensive Care Unit

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this prospective observational study is to evaluate whether left ventricular function parameters assessed via transthoracic echocardiography (TTE) can predict weaning success from mechanical ventilation in adult intensive care unit (ICU) patients. The main questions it aims to answer are: Can the Left Ventricular Outflow Tract Velocity Time Integral (LVOT VTI) predict successful extubation? What is the prognostic value of other echocardiographic measures such as Mitral Annular Plane Systolic Excursion (MAPSE), E/e' ratio, E/A ratio, Mitral Deceleration Time (MDT), and Myocardial Performance Index (Tei index) in forecasting weaning outcomes? Participants will: Be adults receiving mechanical ventilation and scheduled for weaning Undergo transthoracic echocardiography (TTE) within 2 hours after meeting weaning criteria Have the following parameters measured: LVOT VTI, MAPSE, E/e', E/A, MDT, and Tei index Be monitored for 24 hours post-extubation to determine if they remain off ventilatory support, including reintubation, non-invasive ventilation, or high-flow oxygen therapy This study aims to provide a comprehensive understanding of how systolic, diastolic, and global cardiac functions influence extubation success, potentially improving ICU decision-making and reducing complications, length of stay, and healthcare costs.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-10; most recent amendment 2025-09-02.
Status change: Not Yet Recruiting → Recruiting 2025-09-02
Trial Details
NCT Number NCT07075926
Lead Sponsor Kanuni Sultan Suleyman Training and Research Hospital
Conditions Weaning Failure of Mechanical Ventilation
Enrollment 50 participants
Start Date 2025-07-31
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-07-16 (estimated)
Updated on ClinicalTrials.gov 2025-09-09